公开(公告)号：US20240350605A1

公开(公告)日：2024-10-24

申请号：US18688336

申请日：2022-08-31

申请人： Elixirgen Therapeutics, Inc.

发明人： Minoru S.H. KO

IPC分类号： A61K39/00 ,  A61K9/00 ,  A61K47/36 ,  A61P35/00 ,  C07K14/005 ,  C07K14/47 ,  C12N15/86

CPC分类号： A61K39/001189 ,  A61K9/0021 ,  A61K39/00115 ,  A61K39/001153 ,  A61K39/001186 ,  A61K39/001188 ,  A61K47/36 ,  A61P35/00 ,  C07K14/005 ,  C07K14/4748 ,  C12N15/86 ,  A61K2039/53 ,  A61K2039/54 ,  A61K2039/572 ,  A61K2039/575 ,  A61K2039/70 ,  C07K2319/02 ,  C12N2770/36122 ,  C12N2770/36134 ,  C12N2770/36143 ,  C12N2810/855

摘要： The present disclosure relates to mRNA, self-replicating RNA, and temperature-sensitive, self-replicating RNA encoding a cancer antigen. The RNA constructs are suitable for cancer immunotherapy in a mammalian subject, such as a human subject.

公开(公告)号：US20240350598A1

公开(公告)日：2024-10-24

申请号：US18650535

申请日：2024-04-30

申请人： AC Immune SA

发明人： Emma Fiorini ,  Marija Vukicevic Verhille ,  Maria Pihlgren Bosch

IPC分类号： A61K39/00 ,  A61K9/127 ,  A61K39/05 ,  A61K39/08 ,  A61K39/245 ,  A61K39/39 ,  A61P25/28 ,  C07K14/005

CPC分类号： A61K39/0007 ,  A61K9/127 ,  A61K39/0003 ,  A61K39/0005 ,  A61K39/05 ,  A61K39/08 ,  A61K39/245 ,  A61K39/39 ,  A61P25/28 ,  C07K14/005 ,  A61K2039/55516 ,  A61K2039/55555 ,  A61K2039/55572 ,  A61K2039/57 ,  A61K2039/575 ,  A61K2039/58 ,  A61K2039/627 ,  A61K2039/645 ,  A61K2039/70 ,  C07K2319/33 ,  C07K2319/55 ,  C12N2710/16232 ,  C12N2710/16234 ,  C12N2760/16033

摘要： A liposomal vaccine composition comprises a β-amyloid (Aβ)-derived peptide antigen displayed on the surface of the liposome. The vaccine composition also comprises a peptide comprising a universal T-cell epitope encapsulated within the liposome. The vaccine composition also comprises an adjuvant, which may form part of the liposome and may be displayed at least in part on the surface of the liposome. These vaccine compositions are used for treating, preventing, inducing a protective immune response against or alleviating the symptoms associated with an amyloid-beta associated disease or condition or a condition characterised by, or associated with, loss of cognitive memory capacity in a subject. The vaccine compositions may be provided as a kit. Related methods of producing a liposomal vaccine composition are also provided.

公开(公告)号：US20240335528A1

公开(公告)日：2024-10-10

申请号：US18751109

申请日：2024-06-21

申请人： VLP Therapeutics Japan, Inc.

发明人： Wataru Akahata ,  Jonathan F. Smith ,  Jeffery Leo Alexander ,  Takashi Sekida

IPC分类号： A61K39/215 ,  A61K39/00 ,  A61P31/14 ,  C07K14/005 ,  C12N7/00

CPC分类号： A61K39/215 ,  A61P31/14 ,  C07K14/005 ,  C12N7/00 ,  A61K2039/5256 ,  A61K2039/70 ,  C12N2760/16134 ,  C12N2770/20034 ,  C12N2770/36122 ,  C12N2770/36134

摘要： ABSTRACT OF DISCLOSURE Provided herein is a bivalent alphavirus replicon vaccine, which is a combination of a first polynucleotide which encodes alphavirus non-structural proteins nsp1, nsp2, nsp3 and nsp4 and an antigenic peptide and a second polynucleotide which encodes alphavirus non-structural proteins nsp1, nsp2, nsp3 and nsp4 and a CD8+ T cell epitope. The vaccine is useful against virus infection, especially, COVID-19 or SARS-COV-2 infection, the treatment of a cancer and/or an inflammatory disease.

公开(公告)号：US20240325516A1

公开(公告)日：2024-10-03

申请号：US18741232

申请日：2024-06-12

申请人： Biological E Limited

发明人： Rajendar Burki ,  Vivek Babu Kandimalla ,  Rajan Sriraman ,  Ramesh Venkat Matur ,  Narender Dev Mantena ,  Mahima Datla ,  Veerapandu Sangareddy

IPC分类号： A61K39/09 ,  A61K31/715 ,  A61K39/00 ,  A61K47/62 ,  C08B37/00

CPC分类号： A61K39/092 ,  A61K31/715 ,  A61K47/62 ,  C08B37/0003 ,  A61K2039/6037 ,  A61K2039/70

摘要： The invention relates to capsular polysaccharides of Streptococcus pneumoniae. More specifically, the present invention relates to sized and purified capsular polysaccharides of Streptococcus pneumoniae serotypes 2, 15A, 15C & 35B and process for their preparation.

公开(公告)号：US20240317833A1

公开(公告)日：2024-09-26

申请号：US18381081

申请日：2023-10-17

申请人： PDS BIOTECHNOLOGY CORPORATION

发明人： Frank Bedu-Addo ,  Joseph Dervan ,  Gregory Conn

IPC分类号： C07K14/725 ,  A61K39/00 ,  A61K45/06 ,  A61P35/00

CPC分类号： C07K14/7051 ,  A61K45/06 ,  A61P35/00 ,  A61K2039/55555 ,  A61K2039/55572 ,  A61K2039/70

摘要： Novel compositions of TCR Gamma Alternate Reading Frame Protein (TARP) peptides combined with cationic lipids such as the DOTAP and specifically R-DOTAP, induce high levels of TARP-specific polyfunctional cytolytic T-cells. Compositions and methods of use are provided. The compositions comprise N-terminal and C-terminal overlapping peptide sequence pairs duplicating the critical central antigenic region of TARP and encompassing the entire protein selected and designed to be effectively processed by antigen-presenting cells to prime cytotoxic T cells specific for TARP-derived T cell peptide antigens when delivered in combination with immunostimulatory nanoparticles composed of R-DOTAP cationic lipids.

公开(公告)号：US20240317828A1

公开(公告)日：2024-09-26

申请号：US18381979

申请日：2023-10-19

申请人： PDS BIOTECHNOLOGY CORPORATION

发明人： Frank Bedu-Addo ,  Joseph Dervan ,  Gregory Conn

IPC分类号： C07K14/47 ,  A61K38/00 ,  A61K39/00

CPC分类号： C07K14/4727 ,  A61K38/00 ,  A61K2039/55555 ,  A61K2039/572 ,  A61K2039/585 ,  A61K2039/70

摘要： Provided herein are multiepitope peptides including at least one mucin 1 (MUC1) peptide, the multiepitope peptides have MHC affinity for at least one of HLA serotype and are recognized by a CD4+ T cell receptor and/or by a CD8+ T cell receptor. Also provided herein are compositions comprising the multiepitope peptides and a cationic lipid, including vaccine compositions. In various aspects, the cationic lipid is R-DOTAP. The invention also provides methods of use of the multiepitope peptides and of the compositions and vaccine compositions. The methods of use include methods of treating cancer and method of inducing a MUC-specific polyfunctional cytolytic T cell response in a subject.

公开(公告)号：US20240316176A1

公开(公告)日：2024-09-26

申请号：US18490287

申请日：2023-10-19

申请人： Children's Hospital Medical Center

发明人： Ming Tan ,  Xi Jiang

IPC分类号： A61K39/12 ,  A61K39/00 ,  A61K39/385 ,  A61P31/14 ,  C07K14/005 ,  C12N7/00

CPC分类号： A61K39/12 ,  A61K39/385 ,  A61P31/14 ,  C07K14/005 ,  C12N7/00 ,  A61K2039/6075 ,  A61K2039/64 ,  A61K2039/70 ,  C07K2319/33 ,  C12N2770/16022 ,  C12N2770/16034

摘要： Disclosed herein are vaccine compositions, in particular, polyvalent icosahedral compositions for antigen presentation. The disclosed compositions may contain an S particle made up of recombinant fusion proteins. The recombinant fusion proteins may include a norovirus (NoV) S domain protein, a linker protein domain operatively connected to the norovirus S domain protein, and an antigen protein domain operatively connected to said linker.

公开(公告)号：US20240309053A1

公开(公告)日：2024-09-19

申请号：US18665309

申请日：2024-05-15

申请人： The United States of America, as represented by the Secretary, Department of Health and Human Servic

发明人： Peter Collins ,  Bo Liang ,  Shirin Munir ,  Anne Schaap Nutt ,  Ursula Buchholz ,  Natalie Mackow ,  Peter Kwong ,  Barney Graham ,  Jason McLellan

IPC分类号： C07K14/005 ,  A61K39/00 ,  A61K39/12 ,  A61K39/155 ,  A61P31/14

CPC分类号： C07K14/005 ,  A61K39/12 ,  A61K39/155 ,  A61P31/14 ,  A61K2039/5254 ,  A61K2039/5256 ,  A61K2039/575 ,  A61K2039/70 ,  C07K2319/03 ,  C07K2319/033 ,  C12N2760/00022 ,  C12N2760/18534 ,  C12N2760/18571 ,  C12N2760/18622 ,  C12N2760/18634 ,  C12N2760/18641 ,  C12N2760/18643 ,  C12N2760/18671 ,  C12N2760/18722 ,  C12N2760/18734 ,  C12N2760/18741 ,  C12N2760/18743 ,  C12N2760/18771

摘要： Recombinant paramyxoviruses including a viral genome encoding a heterologous gene are provided. In several embodiments, the recombinant paramyxovirus is a recombinant parainfluenza virus, such as a recombinant PIV3 including a viral genome encoding a heterologous respiratory syncytial virus F ectodomain linked to the transmembrane domain and the cytoplasmic tail of the F protein from the PIV3. Nucleic acid molecules including the genome of a recombinant paramyxoviruses are also provided. The recombinant viruses may advantageously be used in vaccine formulations, such as for vaccines against parainfluenza virus and respiratory syncytial virus.

公开(公告)号：US12090195B2

公开(公告)日：2024-09-17

申请号：US17284529

申请日：2019-10-04

申请人： SERUM INSTITUTE OF INDIA PRIVATE LTD

发明人： Inder Jit Sharma ,  Rakesh Kumar ,  Jaganathan Semburakkiannan Kilvani ,  Manohar Doddapaneni ,  Anil Vyankatrao Shitole

IPC分类号： A61K39/00 ,  A61K39/102 ,  A61K39/13 ,  A61K39/29 ,  A61K39/295 ,  A61K47/10 ,  A61K47/14 ,  A61P31/04 ,  A61P31/12 ,  C12N7/00 ,  A61K39/10

CPC分类号： A61K39/0018 ,  A61K39/102 ,  A61K39/13 ,  A61K39/292 ,  A61K39/295 ,  A61K47/10 ,  A61K47/14 ,  A61P31/04 ,  A61P31/12 ,  C12N7/00 ,  A61K2039/10 ,  A61K2039/521 ,  A61K2039/5252 ,  A61K2039/55505 ,  A61K2039/6037 ,  A61K2039/70

摘要： The present disclosure relates to a fully liquid immunogenic composition comprising a combination of antigens/immunogens. The immunogenic composition comprises optimum amount of antigens/immunogens to confer protection against a number of diseases. The composition exhibits improved immunogenicity and stability. A process for preparing the vaccine composition is also disclosed.

公开(公告)号：US12083174B2

公开(公告)日：2024-09-10

申请号：US17268647

申请日：2019-08-16

申请人： GLAXOSMITHKLINE BIOLOGICALS SA

发明人： Sylvie Bertholet Girardin ,  Arun Kumar

IPC分类号： A61K39/145 ,  A61K39/00

CPC分类号： A61K39/145 ,  A61K2039/53 ,  A61K2039/55555 ,  A61K2039/55566 ,  A61K2039/70

摘要： The present invention is in the field of treating and/or preventing viral infections. In particular, the present invention relates to immunogenic or pharmaceutical compositions comprising self-replicating RNA molecules that encode influenzavirus antigens for treating and/or preventing influenza infections.